- Decrease font
- Increase font
- Send to a friend
Click here to bookmark this page
Customize your Bookmarks:
- Type the name of the page the way you would like it to appear in "My Bookmarks";
- Click in the "Add as My Bookmarks" button.
To choose your favorite sessions, please click here.
Grupo Fleury’s executive officers are responsible for representing the Company and for the day-to-day management of its business. They have the authority to do all acts necessary or appropriate for that purpose, except those the Brazilian corporate law or Fleury’s bylaws reserve for its shareholders’ meeting or board of directors.
Under the Company’s bylaws, the executive management of Fleury must be composed of at least three and up to ten members, elected and dismissed at any time by the Board of Directors. Fleury’s executive officers serve a two-year term that coincides with the term of the Company’s board of directors, with reelection permitted.
|Executive officers||Title||End of term of office|
|Carlos Alberto Iwata Marinelli||Chief Executive Officer||BDM after ASM in 2021|
|Claudio Almeida Prado||Operations Support||BDM after ASM in 2021|
|Edgar Gil Rizzatti||Medical, Technical and Process Officer||BDM after ASM in 2021|
|Fernando Augusto Rodrigues Leão Filho||Chief Financial and Investor Relations Officer||BDM after ASM in 2021|
|Jeane Tsutsui||Brands Officer||BDM after ASM in 2021|
|José Roberto Araújo||Commercial and B2B Officer||BDM after ASM in 2021|
Carlos Alberto Iwata Marinelli. In 2005 Carlos Marinelli joined Grupo Fleury, what is today one of the largest organizations dedicated to healthcare and diagnostics in Latin America, processing more than 70 million tests per year in a wide range of areas as Clinical Pathology, Imaging and Genomics. During the last 14 years Mr. Marinelli has held prominent positions in the Company in New Business, Strategy, Innovation, Sustainability and Business Operations. He became CEO in September 2014 - the first to hold the position without belonging to the Company‘s founding physicians’ (founding) shareholders block. During his tenure as CEO Mr. Marinelli transformed the business management model of the company leveraging results and customer satisfaction to historical record levels in Grupo Fleury and the diagnostic medicine sector. Over the last three years, since 2016, he has been elected as the best CEO of the healthcare sector in Latin America by Institutional Investor Magazine. He currently serve as board member of the American Chamber of Commerce in São Paulo and Grupo Papaiz, a diagnostic company for dental imaging. He holds a bachelor‘s and master‘s degree from the School of Business Administration of São Paulo (FGV), with extensions by the University of Texas at Austin (USA) and ESADE Business School (Barcelona). His background also includes executive education from the London Business School, INSEAD and Harvard. Carlos Marinelli worked for Unilever, Grupo Promon and Grupo Pão de Açúcar prior joining the Company.
Claudio Almeida Prado. Mr. Prado joined grupo Fleury in 2016 as Operations Support Executive Director. With a degree in Electrical Engineering and a master‘s degree in Computer Engineering from the Polytechnic School of the University of São Paulo, Claudio was the CEO of Total Express, the logistics company of Grupo Abril, where he was since 2012 and previously held the role of Director of Operations and IT. Previously he has served as Director of IT at Deutsche Bank, a position he also held at Banco Santander from 2008 to 2011. He was also in charge of executive leadership in IT and IT Innovation at ABN Amro Real from 2005 to 2008. Claudio also acted as CEO ahead of the Electronic Platform S.A., a company dedicated to the development of e-commerce software and internet banking (2001-2004), among other solid professional experience.
Edgar Rizzatti. Mr. Rizzatti has an MD from Medical School of Ribeirão Preto at the University of São Paulo, residency in Internal Medicine and fellowship in Hematology and Blood Banking from the Clinics Hospital of Ribeirão Preto of the University of São Paulo. He has a PhD in Medical Sciences from the University of São Paulo, a visiting fellowship from the National Institutes of Health, in Bethesda, MD, and an Executive MBA from Fundação Dom Cabral. Mr. Rizzatti first started at Fleury in 2007 as a consultant physician in Hematology. Since then, he has hold administrative positions in R&D, knowledge management and Laboratory Medicine.
Fernando Augusto Rodrigues Leão Filho. Mr. Leão has accumulated experience as Chief Financial Officer in Israelite Hospital Albert Einstein (2013 to 2017), Chief Financial Officer at Laureate Education (2009 to 2013) and executive positions at Schering-Plow, Johnson & Johnson and other companies. Fernando holds a degree in Civil Engineering from the Federal University of Minas Gerais, an MBA in Capital Markets from IBMEC and a Master‘s degree in Business Administration from the University of Maryland.
Jeane Tsuitsui. Mrs. Tsuitsui is graduated in Medicine from Faculdade de Medicina de Ribeirão Preto - USP, having gone through Clinical Medicine Residency at USP’s Hospital das Clínicas and Cardiology residency at Incor-USP. She has a PhD in Cardiology from Faculdade de Medicina da USP, a post-doctorate from the University of Nebraska’s Medical Center, and is a Full Professor at Faculdade de Medicina da USP. In 2009, she finished her MBA in Knowledge, Innovation and Technology at FIA. She started her career at Fleury in 2001 as a Cardiology doctor and has held a number of positions at the company as Manager, Senior Manager and Director of R&D Knowledge Management.
José Roberto Araújo. Mr. Araújo joined the Company in 2001. Since then he held positions in the technical area and as Commercial, Business Development and B2B Director. Previously, he worked in a multinational company of equipment and reagent for laboratory diagnosis. He holds a degree in Biomedicine, with an MBA in Management of Hospital Organizations and Health Systems from Fundação Getúlio Vargas (FGV).